Boston-based healthcare venture capital firm Omega Funds closed its seventh and largest fund with $650 million in capital commitments, handily beating its $500 million target on the back of strong support from new as well as existing limited partners. Omega Fund VII also significantly outpaced its predecessor, as Fund VI closed with $438 million in December 2019.
Omega said Fund VII is "stage-agnostic," meaning its investments will run the gamut from seed founding to early venture rounds and later-stage financings, albeit with a focus on companies in the U.S. and Europe.
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.